-
NIDCR Small Research Grants for Oral Health Data Analysis and Statistical Methodology Development (R03 Clinical Trial Not Allowed)
(PAR-19-145)
National Institute of Dental and Craniofacial Research
Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
The first standard application due date for this FOA is February 16, 2019.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Drug Discovery For Nervous System Disorders (R21 Clinical Trial Not Allowed)
(PAR-19-146)
National Institute of Mental Health
National Institute on Alcohol Abuse and Alcoholism
National Institute on Aging
National Institute on Drug Abuse
Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
The first standard application due date for this FOA is ?February 16, 2019.
-
Drug Discovery For Nervous System Disorders (R01 Clinical Trials Not Allowed)
(PAR-19-147)
National Institute of Mental Health
National Institute on Alcohol Abuse and Alcoholism
National Institute on Aging
National Institute on Drug Abuse
Application Receipt Date(s): Standard dates apply by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
The first standard application due date for this FOA is February 5, 2019.
-
Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)
(PAR-19-149)
National Cancer Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)
(PAR-19-150)
National Cancer Institute
Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Independent Basic Experimental Studies with Humans Required)
(PAR-19-151)
National Institute of Dental and Craniofacial Research
Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
-
NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Independent Clinical Trial Not Allowed)
(PAR-19-152)
National Institute of Dental and Craniofacial Research
Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
-
End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R21 Clinical Trial Optional)
(PAR-19-153)
National Institute of Nursing Research
National Cancer Institute
Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
The first standard application due date for this FOA is February 16, 2019.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)
(PAR-19-155)
National Heart, Lung, and Blood Institute
Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
The first standard application due date for this FOA is ?February 16, 2019.
-
Bioengineering Research Partnerships (U01 Clinical Trial Not Allowed)
(PAR-19-156)
National Institute of Biomedical Imaging and Bioengineering
National Institute on Alcohol Abuse and Alcoholism
National Institute on Aging
National Cancer Institute
National Institute of Environmental Health Sciences
National Eye Institute
Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Bioengineering Research Partnerships (U01 Clinical Trial Required)
(PAR-19-157)
National Institute of Biomedical Imaging and Bioengineering
National Institute on Alcohol Abuse and Alcoholism
National Institute on Aging
National Cancer Institute
National Eye Institute
Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)
(PAR-19-158)
National Institute of Biomedical Imaging and Bioengineering
National Institute on Alcohol Abuse and Alcoholism
National Institute on Aging
National Institute of Allergy and Infectious Diseases
National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Cancer Institute
National Institute of Dental and Craniofacial Research
National Institute of Environmental Health Sciences
National Eye Institute
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute of Neurological Disorders and Stroke
Application Receipt Date(s): Standard dates apply , by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Bioengineering Research Grants (BRG) (R01 Clinical Trial Required)
(PAR-19-159)
National Institute of Biomedical Imaging and Bioengineering
National Institute on Alcohol Abuse and Alcoholism
National Institute on Aging
National Cancer Institute
National Eye Institute
National Institute of Neurological Disorders and Stroke
Application Receipt Date(s): Standard dates apply , by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
NIDCR Mentored Career Development Award to Promote Diversity in the Dental, Oral and Craniofacial Workforce (K01 Independent Clinical Trial Not Allowed)
(PAR-19-160)
National Institute of Dental and Craniofacial Research
Application Receipt Date(s): Standard dates apply by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
-
NIDCR Mentored Career Development Award to Promote Diversity in the Dental, Oral and Craniofacial Workforce (K01 Independent Basic Experimental Studies with Humans Required)
(PAR-19-161)
National Institute of Dental and Craniofacial Research
Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
-
Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R01-Clinical Trial Not Allowed)
(PAR-19-162)
National Institute on Drug Abuse
National Institute on Alcohol Abuse and Alcoholism
National Cancer Institute
National Institute of Environmental Health Sciences
National Institute of Mental Health
National Center for Complementary and Integrative Health
Office of Research on Women's Health
National Institute on Minority Health and Health Disparities
Application Receipt Date(s): Standard dates apply by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
-
Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed)
(PAR-19-163)
National Institute on Drug Abuse
National Institute on Alcohol Abuse and Alcoholism
National Cancer Institute
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute of Mental Health
National Institute of Neurological Disorders and Stroke
Office of Research on Women's Health
National Institute on Minority Health and Health Disparities
Application Receipt Date(s): Standard dates apply by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
-
Summer Research Education Experience Program (Clinical Trials Not Allowed R25)
(PAR-19-164)
National Institute on Alcohol Abuse and Alcoholism
National Institute on Drug Abuse
National Institute of Environmental Health Sciences
National Institute of Neurological Disorders and Stroke
National Institute of Biomedical Imaging and Bioengineering
Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
The Experimental Therapeutics Clinical Trials Network (UM1 Clinical Trials Required)
(RFA-CA-19-007)
National Cancer Institute
Application Receipt Date(s): May 22,2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
No late applications will be accepted for this Funding Opportunity Announcement.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
The Experimental Therapeutics Clinical Trials Network (ETCTN) Pharmacokinetic Resource Laboratories (U24 Clinical Trials Not Allowed)
(RFA-CA-19-008)
National Cancer Institute
Application Receipt Date(s): May 22, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21 Clinical Trials Not Allowed)
(RFA-CA-19-019)
National Cancer Institute
Application Receipt Date(s): March 7, 2019; May 28, 2019; September 27, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trials Not Allowed)
(RFA-CA-19-020)
National Cancer Institute
Application Receipt Date(s): March 7, 2019; May 28, 2019; September 27, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21 Clinical Trials Not Allowed)
(RFA-CA-19-021)
National Cancer Institute
Application Receipt Date(s): March 7, 2019; May 28, 2019; September 27, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trials Not Allowed)
(RFA-CA-19-022)
National Cancer Institute
Application Receipt Date(s): March 7, 2019; May 28, 2019; September 27, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)
(RFA-CA-19-023)
National Cancer Institute
Application Receipt Date(s): March 7, 2019; May 28, 2019; September 27, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Revisions for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional)
(RFA-CA-19-024)
National Cancer Institute
Application Receipt Date(s): March 7, 2019; May 28, 2019; September 27, 2019), by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U54 Clinical Trials Optional)
(RFA-CA-19-025)
National Cancer Institute
Application Receipt Date(s): March 7, 2019; May 28, 2019; September 27, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P01 Clinical Trial Optional)
(RFA-CA-19-026)
National Cancer Institute
Application Receipt Date(s): March 7, 2019; May 28, 2019; September 27, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)
(RFA-CA-19-027)
National Cancer Institute
Application Receipt Date(s): March 7, 2019; May 28, 2019; September 27, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U2C Clinical Trial Optional)
(RFA-CA-19-028)
National Cancer Institute
Application Receipt Date(s): March 7, 2019; May 28, 2019; September 27, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Improving Outcomes for Pediatric, Adolescent and Young Adult Cancer Survivors (U01 Clinical Trial Required)
(RFA-CA-19-033)
National Cancer Institute
Application Receipt Date(s): March 15, 2019; January 3, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
No late applications will be accepted for this Funding Opportunity Announcement.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Mobile Technologies Extending Reach of Primary Care for Substance-Use-Disorders (R43/R44 Clinical Trial Optional)
(RFA-DA-19-021)
National Institute on Drug Abuse
Application Receipt Date(s): March 19, 2019, by 5:00 PM local time of applicant organization.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Mobile Technologies Extending Reach of Primary Care for Substance-Use-Disorders (R41/R42 Clinical Trial Optional)
(RFA-DA-19-022)
National Institute on Drug Abuse
Application Receipt Date(s): March 19, 2019, by 5:00 PM local time of applicant organization.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Virtual Reality Tools to Enhance Evidence Based Treatment of Substance Use Disorders (R41/R42 - Clinical Trial Optional)
(RFA-DA-19-032)
National Institute on Drug Abuse
Application Receipt Date(s): March 20, 2019
by 5:00 PM local time of applicant organization.
-
Virtual Reality Tools to Enhance Evidence Based Treatment of Substance Use Disorders (R43/R44 - Clinical Trial Optional)
(RFA-DA-19-033)
National Institute on Drug Abuse
Application Receipt Date(s): March 20, 2019
, by 5:00 PM local time of applicant organization.
-
Type 1 Diabetes TrialNet Clinical Network Hub (U01 Clinical Trial Not Allowed)
(RFA-DK-18-008)
National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Date(s): March 21, 2019 by 5:00 PM local time of applicant organization.
All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
-
Limited Competition for the Continuation of the Coordinating Center for Type 1 Diabetes TrialNet (U01 Clinical Trial Required)
(RFA-DK-18-509)
National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Date(s): March 21, 2019 by 5:00 PM local time of applicant organization.
All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date?.
-
The Human Biomolecular Atlas Program (HuBMAP): Rapid Implementation of Technologies that Will Accelerate Development of a Framework for Mapping the Human Body at High Resolution (UH3 Clinical Trial Not Allowed)
(RFA-RM-19-002)
Office of Strategic Coordination (Common Fund)
Application Receipt Date(s): March 14, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.